A Placebo Controlled, Double-blind, Randomised Trial Investigating Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics After Intravenous Administration of FE 204205 in Patients With Cirrhotic Portal Hypertension

Trial Profile

A Placebo Controlled, Double-blind, Randomised Trial Investigating Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics After Intravenous Administration of FE 204205 in Patients With Cirrhotic Portal Hypertension

Discontinued
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs FE 204205 (Primary)
  • Indications Portal hypertension
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 11 Oct 2017 Status changed from recruiting to discontinued due to difficulty in recruitment
    • 07 Feb 2017 Planned End Date changed from 1 Apr 2017 to 1 Feb 2018.
    • 07 Feb 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top